相关实验视频

Updated: Jun 30, 2025

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

在囊性纤维化中,CFTR调节器与缺铁标志物的变化之间存在关联

Shijing Jia¹, Yizhuo Wang², Melissa H Ross¹

¹Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

|March 15, 2024

概括

在囊性纤维化 (CF) 患者中,高效调节剂疗法 (HEMT) 显著改善了铁缺乏症标志物,如转林和和血清铁. 然而,尽管使用HEMT,铁缺乏仍然很普遍.

科学领域:

肺部医学肺部医学
血液学血液学血液学
药理学药理学是指药理学的学科.

背景情况:

铁缺乏症 (ID) 是囊性纤维化 (CF) 的常见肺外并发症.
肌痛性结核病的跨膜导电调节器 (CFTR) 调节器疗法,特别是高效调节器疗法 (HEMT),大大改善了许多CF患者的健康结果.
这项研究调查了CFTR调节器使用与改进的ID标记器之间的潜在联系.

研究的目的:

为了确定CFTR调节器治疗是否与囊性纤维化患者的铁缺乏标志物改善有关.
分析调节器疗法与与缺铁相关的实验室结果之间的关联.

主要方法:

从2012年到2022年,在美国四个CF中心进行了一项多中心回顾性队列研究.
使用多变量线性混合效应模型来估计调节器疗法与ID实验室结果之间的关联.
铁缺乏症被定义为转林和度 (TSAT) <20%或血清铁<60μg/dL.

主要成果:

高效调节剂治疗 (HEMT) 与没有调节剂治疗相比,与TSAT (+8.4%) 和血清铁 (+34.4μg/dL) 的显著增加有关.
在女性 (+5.4% TSAT, +22.1 μg/dL血清铁) 和男性 (+11.4% TSAT, +46.0 μg/dL血清铁) 分组中观察到TSAT和血清铁的改善.
虽然调节剂治疗时血红蛋白水平较高,但费里水平没有显著差异. 智障的患病率仍然很高 (32.8%的HEMT使用者).

结论:

铁缺乏症仍然是囊性纤维化患者常见的并发症,即使有HEMT的可用性.
CFTR调节剂疗法,特别是HEMT,与铁缺乏症 (TSAT,血清铁) 和贫血 (血红蛋白) 的关键标志物的改善有关.

关键词:

贫血贫血是一种疾病.在CFTR调节器疗法中.囊性纤维化症是什么铁缺乏症铁缺乏症营养营养营养营养营养

更多相关视频

Rectal Organoid Morphology Analysis ROMA: A Diagnostic Assay in Cystic Fibrosis

Rectal Organoid Morphology Analysis ROMA: A Diagnostic Assay in Cystic Fibrosis

Published on: June 10, 2022

The Caco-2 Cell Bioassay for Measurement of Food Iron Bioavailability

The Caco-2 Cell Bioassay for Measurement of Food Iron Bioavailability

Published on: April 28, 2022

相关概念视频

Cystic Fibrosis: Pathogenesis

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...

Cystic Fibrosis: Management

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...